Allergan PLC.’s (AGN) “Buy” Rating Reaffirmed at Citigroup Inc.
Other analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Allergan PLC. from a hold rating to a buy rating and set a $270.00 price target for the company in a report on Tuesday, July 11th. BidaskClub raised shares of Allergan PLC. from a hold rating to a buy rating in a report on Saturday, June 24th. Royal Bank Of Canada set a $284.00 price target on shares of Allergan PLC. and gave the company a buy rating in a report on Monday, June 12th. Mizuho lowered their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a buy rating for the company in a report on Friday, June 9th. Finally, Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a buy rating in a report on Thursday, June 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Allergan PLC. currently has an average rating of Buy and an average price target of $273.34.
Allergan PLC. (AGN) opened at 210.00 on Wednesday. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The stock’s 50 day moving average price is $229.79 and its 200 day moving average price is $236.07. The firm has a market capitalization of $70.20 billion, a P/E ratio of 6.40 and a beta of 1.18.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company’s revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the business posted $3.35 earnings per share. On average, analysts forecast that Allergan PLC. will post $16.25 earnings per share for the current year.
WARNING: “Allergan PLC.’s (AGN) “Buy” Rating Reaffirmed at Citigroup Inc.” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/21/allergan-plc-s-agn-buy-rating-reaffirmed-at-citigroup-inc.html.
The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.33%. Allergan PLC.’s dividend payout ratio is 9.95%.
Large investors have recently modified their holdings of the stock. Howard Hughes Medical Institute acquired a new stake in shares of Allergan PLC. during the second quarter worth $103,000. Jacobi Capital Management LLC raised its holdings in shares of Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after acquiring an additional 22 shares during the period. JNBA Financial Advisors raised its holdings in shares of Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after acquiring an additional 12 shares during the period. Massey Quick & Co. LLC raised its holdings in shares of Allergan PLC. by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after acquiring an additional 385 shares during the period. Finally, Pacific Center for Financial Services raised its holdings in shares of Allergan PLC. by 805.1% during the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after acquiring an additional 475 shares during the period. Institutional investors and hedge funds own 82.02% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.